Joshua Tobias

Hospital de Especialidades — Mexico

Medicine · Health Sciences

25h-index1.9kcitations105works1.02yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Monoclonal and Polyclonal Antibodies Research(55), Cancer Immunotherapy and Biomarkers(33), Immunotherapy and Immune Responses(32), Gastric Cancer Management and Outcomes(30), Escherichia coli research studies(27)

Publications105 total

Entamoeba histolytica – binding of the lipopeptidophosphoglycan - specific monoclonal antibody EH5 to dextrans
Carbohydrate Research·2025Open Access
Clinician perspectives on the multilevel impacts of Pediatric early warning systems (PEWS) in resource-variable hospitals
Frontiers in Oncology·2025· 1 citedOpen Access
Abstract P1-07-15: Tumor size reduction and overall survival improvement in HER2-overexpressing cancer patients vaccinated with HER-Vaxx, a B-cell peptide-based vaccine, plus standard-of-care chemotherapy
Clinical Cancer Research·2025· 1 cited
Multilevel mortality risk factors among pediatric hematology‐oncology patients with deterioration
Cancer·2025· 2 citedOpen Access
The benefits of Lactiplantibacillus plantarum: From immunomodulator to vaccine vector
Immunology Letters·2025· 3 citedOpen Access
Documenting adaptations to an evidence-based intervention in 58 resource-variable pediatric oncology hospitals across implementation phases
Implementation Science Communications·2024· 2 citedOpen Access
Supplementary Figure S8 from Phase II Trial of HER-Vaxx, a B-cell Peptide-Based Vaccine, in HER2-Overexpressing Advanced Gastric Cancer Patients Under Platinum-Based Chemotherapy (HERIZON)
2024Open Access
Supplementary Table S1 from Phase II Trial of HER-Vaxx, a B-cell Peptide-Based Vaccine, in HER2-Overexpressing Advanced Gastric Cancer Patients Under Platinum-Based Chemotherapy (HERIZON)
2024Open Access
Supplementary Table S4 from Phase II Trial of HER-Vaxx, a B-cell Peptide-Based Vaccine, in HER2-Overexpressing Advanced Gastric Cancer Patients Under Platinum-Based Chemotherapy (HERIZON)
2024Open Access
Supplementary Table S1 from Phase II Trial of HER-Vaxx, a B-cell Peptide-Based Vaccine, in HER2-Overexpressing Advanced Gastric Cancer Patients Under Platinum-Based Chemotherapy (HERIZON)
2024Open Access
Supplementary Figure S7 from Phase II Trial of HER-Vaxx, a B-cell Peptide-Based Vaccine, in HER2-Overexpressing Advanced Gastric Cancer Patients Under Platinum-Based Chemotherapy (HERIZON)
2024Open Access
Supplementary Figure S4 from Phase II Trial of HER-Vaxx, a B-cell Peptide-Based Vaccine, in HER2-Overexpressing Advanced Gastric Cancer Patients Under Platinum-Based Chemotherapy (HERIZON)
2024Open Access
Supplementary Table S3 from Phase II Trial of HER-Vaxx, a B-cell Peptide-Based Vaccine, in HER2-Overexpressing Advanced Gastric Cancer Patients Under Platinum-Based Chemotherapy (HERIZON)
2024Open Access
Supplementary Figure S2 from Phase II Trial of HER-Vaxx, a B-cell Peptide-Based Vaccine, in HER2-Overexpressing Advanced Gastric Cancer Patients Under Platinum-Based Chemotherapy (HERIZON)
2024Open Access
Supplementary Materials and Methods S1 from Phase II Trial of HER-Vaxx, a B-cell Peptide-Based Vaccine, in HER2-Overexpressing Advanced Gastric Cancer Patients Under Platinum-Based Chemotherapy (HERIZON)
2024Open Access
Supplementary Figure S1 from Phase II Trial of HER-Vaxx, a B-cell Peptide-Based Vaccine, in HER2-Overexpressing Advanced Gastric Cancer Patients Under Platinum-Based Chemotherapy (HERIZON)
2024Open Access
Supplementary Table S3 from Phase II Trial of HER-Vaxx, a B-cell Peptide-Based Vaccine, in HER2-Overexpressing Advanced Gastric Cancer Patients Under Platinum-Based Chemotherapy (HERIZON)
2024Open Access
Supplementary Figure S6 from Phase II Trial of HER-Vaxx, a B-cell Peptide-Based Vaccine, in HER2-Overexpressing Advanced Gastric Cancer Patients Under Platinum-Based Chemotherapy (HERIZON)
2024Open Access
Supplementary Figure S9 from Phase II Trial of HER-Vaxx, a B-cell Peptide-Based Vaccine, in HER2-Overexpressing Advanced Gastric Cancer Patients Under Platinum-Based Chemotherapy (HERIZON)
2024Open Access
Supplementary Figure S1 from Phase II Trial of HER-Vaxx, a B-cell Peptide-Based Vaccine, in HER2-Overexpressing Advanced Gastric Cancer Patients Under Platinum-Based Chemotherapy (HERIZON)
2024Open Access
page 1 of 6Next →

Frequent Co-authors

Ursula Wiedermann(16), Ann‐Mari Svennerholm(15), Michael Lebens(11), Michael Kundi(10), Jan Holmgren(10), Erika Garner‐Spitzer(9), Christoph Zielinski(8), Mirjana Drinić(7), Peter Steinberger(6), Claire Battin(4), Nils Carlin(4), Dani Cohen(4), Åsa Sjöling(4), Sandra Högler(4), Lukas Kenner(4), Karin Baier(3), Stéphanie Longet(3), Vincenzo Aversa(3), Mónica Rosa(3), Ivan S. Coulter(3)